| Carroll Healthcare Center Inc | |
| 648 Longhorn Street, Carrollton, Ohio 44615 | |
| (330) 627-5501 | |
| Name | Carroll Healthcare Center Inc |
|---|---|
| Location | 648 Longhorn Street, Carrollton, Ohio |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 77 |
| Occupancy Rate | 54.42% |
| Medicare ID (CCN) | 365579 |
| Legal Business Name | Carroll Healthcare Center Inc |
| Ownership Type | For Profit - Corporation |
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.
New evidence suggests that it would be appropriate to remove the diagnosis of transgender from its current classification as a mental disorder, according to a study conducted in Mexico City.
Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Bruker BioSpin announces the new Fourier 300, an innovative, easy-to-use 300 MHz high-resolution spectrometer that brings Fourier transform (FT) Nuclear Magnetic Resonance (NMR) spectroscopy within every chemist's reach. With its robust Fourier Probe technology, easy software, miniaturized electronics and proven magnets, the Fourier 300 is a complete proton and carbon 1D and 2D FT-NMR system that delivers powerful performance at an attractive price.
At the forthcoming Lab Innovations 2015, between the 4th and 5th of November at the NEC, Birmingham, UK. Porvair Sciences in association with Asynt will present a masterclass on laboratory evaporation techniques.
› Verified 6 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 10.76 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 3.66 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 45.65 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.64 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.25 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.7 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.83 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 2.65 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 97.87 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 18.51 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 21.3 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 7 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.52 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 51.26 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 100 | 82.93 |
News Archive
Ligand Pharmaceuticals Incorporated announced today that it has entered into a strategic relationship with Chiva Pharmaceuticals, to develop multiple Ligand assets and technology in China and potentially worldwide.
New evidence suggests that it would be appropriate to remove the diagnosis of transgender from its current classification as a mental disorder, according to a study conducted in Mexico City.
Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Bruker BioSpin announces the new Fourier 300, an innovative, easy-to-use 300 MHz high-resolution spectrometer that brings Fourier transform (FT) Nuclear Magnetic Resonance (NMR) spectroscopy within every chemist's reach. With its robust Fourier Probe technology, easy software, miniaturized electronics and proven magnets, the Fourier 300 is a complete proton and carbon 1D and 2D FT-NMR system that delivers powerful performance at an attractive price.
At the forthcoming Lab Innovations 2015, between the 4th and 5th of November at the NEC, Birmingham, UK. Porvair Sciences in association with Asynt will present a masterclass on laboratory evaporation techniques.
› Verified 6 days ago
Carroll Healthcare Center Inc Location: 648 Longhorn Street, Carrollton, Ohio 44615 Phone: (330) 627-5501 |